Excision BioTherapeutics is at the forefront of developing innovative CRISPR-based therapies aimed at curing viral infectious diseases. Their technology focuses on utilizing CRISPR gene-editing capabilities to specifically target and eliminate viral DNA from infected cells. This approach is being applied to a range of viral diseases, including human immunodeficiency virus (HIV), herpes simplex viruses (HSV 1&2), and hepatitis B. The company is actively advancing multiple therapies through clinical trials, demonstrating a commitment to transforming the treatment landscape for patients suffering from chronic viral infections.

The company’s pipeline includes several investigational products, such as EBT-101, EBT-104, and EBT-107, which are designed to address various aspects of viral infections. Excision BioTherapeutics emphasizes the importance of rigorous clinical trial design to ensure the safety and efficacy of their therapies, with ongoing studies aimed at evaluating the potential of their CRISPR-based solutions. By leveraging collaborative partnerships with leading research institutions, Excision aims to bring groundbreaking therapies to market that could significantly improve the quality of life for patients affected by these challenging diseases.

United States

Excision BioTherapeutics is a private company focused on developing advanced gene editing therapeutics to address the medical need for the treatment of life-threatening disease caused by viral infections. Our mission is to advance gene editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Central Nervous System (CNS)

Digestive System Diseases

Infectious Diseases

Nervous System Diseases

Excision BioTherapeutics

Human immunodeficiency virus

EBT-101

Biologics

Gene Therapy

Progressive Multifocal Leukoencephalopathy

EBT-103

Human herpesvirus 6

EBT-104

Hepatitis B

EBT-107

San Francisco, California, United States of America

California - North

California

Adeno-associated viral vector (AAV)

Gene Editing/CRISPR

RNA Therapies

Therapeutic

Excision BioTherapeutics

Company Details